Table 1.
Baseline characteristics of study participants.
| Characteristic | Placebo | Active | p |
|---|---|---|---|
| Age, years | 52.69 ± 2.10 | 52.09 ± 1.71 | 0.931 |
| SBP, mmHg | 134.17 ± 12.87 | 134.26 ± 8.89 | 0.972 |
| DBP, mmHg | 85.17 ± 9.69 | 88.45 ± 8.46 | 0.171 |
| BMI, Kg/m2 | 23.84 ± 2.19 | 23.42 ± 1.81 | 0.355 |
| Total Cholesterol, mg/dL | 171.38 ± 29.23 | 178.03 ± 30.33 | 0.322 |
| HDL Cholesterol, mg/dL | 49.60 ± 21.94 | 50.64 ± 20.71 | 0.818 |
| LDL Cholesterol, mg/dL | 91.24 ± 34.78 | 98.08 ± 34.31 | 0.379 |
| Triglycerides, mg/dL | 108.43 ± 62.97 | 110.11 ± 66.97 | 0.904 |
| ALT, U/L | 22.95 ± 5.93 | 24.13 ± 9.49 | 0.217 |
| AST, U/L | 23.57 ± 4.41 | 24.47 ± 5.25 | 0.406 |
| Glycemia, mg/dL | 93.60 ± 28.98 | 91.08 ± 16.74 | 0.635 |
| DPD, pmol/μmol | 13.73 ± 2.98 | 14.40 ± 3.05 | 0.395 |
| TRACP-5b, U/L | 4.29 ± 0.81 | 4.11 ± 0.91 | 0.422 |
| Osteocalcin, ng/mL | 23.53 ± 5.67 | 22.95 ± 5.20 | 0.679 |
| BAP, μ/mL | 45.77 ± 2.30 | 45.13 ± 3.00 | 0.363 |
| BMD, SD | 0.827 ± 0.097 | 0.867 ± 0.119 | 0.211 |
Abbreviations: SBP, Systolic blood pressure; DBP, Diastolic blood pressure; BMI, body. mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DPD, deoxypyridinoline; TRACP-5b, tartrate-resistant acid phosphatase 5b; BAP, bone-specific alkaline phosphatase; BMD, bone mineral density.